Literature DB >> 17417931

State of diabetes care in the United States.

Lawrence Blonde1.   

Abstract

As of 2005, it was estimated that 7% of the US population, approximately 21 million people, have diabetes. The major concern with diabetes is long-term complications, which are responsible for increased rates of morbidity and mortality. Studies have shown that lower glycosylated hemoglobin reduces the microvascular and macrovascular complications associated with diabetes. To achieve this goal, the American Diabetes Association provides treatment goals to aggressively control diabetes to improve outcomes and decrease morbidity and mortality. Although studies have proved the beneficial effects of currently used agents, there are still various concerns, including weight gain, high risk of hypoglycemia, poor postprandial control, and failure to maintain long-term glycemic control. With the advent of new incretin-related therapies, some of these concerns may be addressed. Diabetes is of growing concern, and better knowledge of treatment options and goals should be a priority for all healthcare professionals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417931

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

1.  Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction.

Authors:  Alexis C Frazier-Wood; W Timothy Garvey; Tara Dall; Robert Honigberg; Ray Pourfarzib
Journal:  Metab Syndr Relat Disord       Date:  2012-04-25       Impact factor: 1.894

2.  Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes.

Authors:  Manuel González-Ortiz; Esperanza Martínez-Abundis; José A Robles-Cervantes; Viridiana Ramírez-Ramírez; Maria G Ramos-Zavala
Journal:  Eur J Nutr       Date:  2010-07-21       Impact factor: 5.614

3.  Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

Authors:  Janice A Kolberg; Torben Jørgensen; Robert W Gerwien; Sarah Hamren; Michael P McKenna; Edward Moler; Michael W Rowe; Mickey S Urdea; Xiaomei M Xu; Torben Hansen; Oluf Pedersen; Knut Borch-Johnsen
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 19.112

4.  Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Authors:  Kristen Kulasa; Steven Edelman
Journal:  Core Evid       Date:  2010-10-21

5.  Expenditures in mental illness and substance use disorders among veteran clinic users with diabetes.

Authors:  Ranjana Banerjea; Usha Sambamoorthi; David Smelson; Leonard M Pogach
Journal:  J Behav Health Serv Res       Date:  2008-05-30       Impact factor: 1.475

6.  Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose.

Authors:  Malkanthi Evans; William V Judy; Dale Wilson; John A Rumberger; Najla Guthrie
Journal:  Diabetes Metab Syndr Obes       Date:  2015-06-25       Impact factor: 3.168

Review 7.  Small artery remodelling in diabetes.

Authors:  Enrico Agabiti Rosei; Damiano Rizzoni
Journal:  J Cell Mol Med       Date:  2010-05       Impact factor: 5.310

8.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.